Thomas John Charles sold $194K of KRYS
Thomas John Charles (EVP, General Counsel) sold 642 shares of Krystal Biotech, Inc. (KRYS) at $302.03 ($0.19M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is under a pre-arranged 10b5-1 plan, it is generally less informative than discretionary selling; without accompanying company news, trading impact should be limited.
Market read
This is an issuer-specific insider sale with no new fundamental catalyst mentioned, suggesting low trading relevance.
What to watch
Insider sales can still matter if paired with other insider activity or if the company simultaneously reports negative clinical/regulatory updates—neither is present here.
Background
The article is an SEC Form 4 insider transaction disclosure for Krystal Biotech (KRYS).
Ticker impact
Krystal Biotech disclosed an EVP/General Counsel open-market sale of 642 shares ($193,903) under a pre-arranged 10b5-1 plan.
Likely minimal immediate price impact; any reaction should be small and short-lived.
Form 4 shows a planned sale (10b5-1) and the article contains no new operating, clinical, or deal catalyst.
Market effects
No direct sector read-across; biotech insider sales under 10b5-1 are common and typically not sector-moving.
None indicated; this is a US SEC insider transaction disclosure.
None indicated beyond the issuer-specific disclosure.
Counterpoint
Treat the sale as liquidity/portfolio management rather than bearish information because it is explicitly pre-arranged under 10b5-1.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the insider transaction disclosure; EVP/General Counsel sold 642 shares under a 10b5-1 plan.
- insiderThomas John Charles
EVP, General Counsel who executed the open-market sale disclosed on Form 4.
